Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
Biopharma Co. Cybin Reports $78M Loss Amid Accelerating Expansion In Psychedelic Therapies, Drug Development
在加速推進的迷幻療法和藥物研發擴張中，生物製藥公司Cybin報告損失7800萬美元。
Cybin Inc. (AMEX:CYBN) (CBOE: CYBN), a clinical-stage biopharmaceutical company focused on developing next-generation psychedelic treatments for mental health disorders, announced Wednesday its financial results for the fiscal quarter and year ending March 31, 2024, alongside significant strides in psychedelic therapy development. Cybin reported a net loss of C$78 million ($57 million) for FY 2024, a noticeable increase from C$47 million the previous year.
臨床階段生物製藥公司Cybin Inc.（AMEX: CYBN）（CBOE: CYBN）專注於開發下一代治療心理健康障礙的致幻藥物治療，週三宣佈其2024財年和截至2024年3月31日的財務業績，以及在致幻療法開發方面取得的重要進展。Cybin宣佈2024財年淨虧損達7800萬加元（5700萬美元），較上一年的4700萬加元有顯著增長。
Fiscal Year 2024 Financial Highlights
2024財年財務亮點
No profits or revenues reported.
Net loss was C$78 million.
Cash totaled C$209 million as of March 31, 2024.
Closed oversubscribed private placement of $150 million led by a syndicate of leading biopharmaceutical institutional investors.
沒有利潤或收入報告。
淨損失爲7800萬加元。
截至2024年3月31日，現金總額爲2.09億加元。
由一群領先的生物製藥機構投資者牽頭，完成了1.5億美元的私募定向增發，認購超額。
Q4 2024 Financial Highlights...
20...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。